Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
weight loss
Biotech
Roche pens $2.5B pact for Hanmi’s muscle-conserving obesity drug
Roche took its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage UCN2 analog from South Korea’s Hanmi.
James Waldron
Aug 24, 2026 4:42am
Amgen drops ph. 1 obesity drug, upping pressure on MariTide
Aug 4, 2026 4:01pm
Lilly triple-G drug hits 22% weight loss, cardio impact unclear
Jul 23, 2026 9:06am
Kailera’s oral GLP-1 asset hits goals in Chinese phase 3 trials
Jul 7, 2026 8:44am
Vincentage to chase Lilly to China regulators after obesity win
May 18, 2026 9:23am
Kailera plots IPO to fund Hengrui-licensed obesity pipeline
Mar 30, 2026 3:45am